Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis

Expert Review of Respiratory Medicine

Volumn 3, Issue 5, 2009, Pages 539-548

  Albertson, Timothy E ^a   Chan, Andrew L ^b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bronchiectasis; Bronchitis; COPD; Elderly patients

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BRONCHODILATING AGENT; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TOBRAMYCIN;

AGED; ANTIBIOTIC THERAPY; BRONCHIECTASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMPHYSEMA; FLUID THERAPY; HAEMOPHILUS INFLUENZAE; HUMAN; MORAXELLA CATARRHALIS; NONHUMAN; NUTRITIONAL SUPPORT; PHYSICAL ACTIVITY; PSEUDOMONAS AERUGINOSA; REST; REVIEW; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; UNSPECIFIED SIDE EFFECT;

EID: 73449086726     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.37     Document Type: Review

References (55)

1. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4, 435-459 (2009).
2. American Thoracic Society, Definitions, epidemiology, pathophysiology, diagnosis, and staging. Am. J. Respir. Crit. Care Med. 152, S78-S83 (1995).
3. Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther. Adv. Respir. Dis. 1, 61-76 (2007).
4. Meyer KC. Aging. Proc. Am. Thorac. Soc. 2, 433-439 (2005).
5. Hayes D Jr, Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. Drugs Aging 24, 555-572 (2007).
6. Brunton S, Carmichael BP, Colgan R et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am. J. Manag. Care 10, 689-696 (2004).
7. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10(Suppl. B), 3B-32B (2003). •• Excellent review of Canadian guidelines in the treatment of acute exacerbation of chronic bronchitis (AECB).
8. Burgel PR, Nesme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 135, 975-982 (2009).
9. Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 123, 1684-1692 (2003).
10. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther. 21, 576-591 (1999).
11. Niederman MS, Anzueto A, Sethi S et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin Phase III trials compared with macrolide agents. Respir. Med. 100, 1781-1790 (2006).
12. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 117, 1S-4S (2000).
13. Connolly MJ, Lowe D, Anstey K, Hosker HS, Pearson MG, Roberts CM, Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation. Thorax 61, 843-848 (2006).
14. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 57, 137-141 (2002).
15. McGuire A, Irwin DE, Fenn P et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 4, 370-375 (2001).
16. Rennie RP, Ibrahim KH. Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin. Infect. Dis. 41(Suppl. 4), S234-S238 (2005).
17. O'Donnell AE. Bronchiectasis. Chest 134, 815-823 (2008).
18. Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 21, 851-864 (2004).
19. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill. Summ. 51, 1-16 (2002).
20. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117, 380S-385S (2000).
21. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106, 196-204 (1987). •• Defines the clinical syndrome of an exacerbation in patients with chronic bronchitis.
22. Patel IS, Vlahos I, Wilkinson TM et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 400-407 (2004).
23. Blasi F, Ewig S, Torres A, Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm. Pharmacol. Ther. 19, 361-369 (2006). •• Provides an excellent review of various guidelines for the treatment of AECB.
24. Martinez FJ, Grossman RF, Zadeikis N et al. Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J. 25, 1001-1010 (2005).
25. Poole P, Chacko EE, Wood-Baker R, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease (Review). Cochrane Database Syst. Rev. 1, CD002733 (2006).
26. O'Donnell DE, Hernandez P, Kaplan A et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can. Respir. J. 15(Suppl. A), 1A-8A (2008).
27. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp. Gerontol. 38, 843-853 (2003).
28. Sin D, Tu J. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. Can. Respir. J. 7(6), 466-471 (2000).
29. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 63, 415-422 (2008).
30. Milstone AP. Use of azithromycin in the treatment of acute exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 3, 515-520 (2008).
31. Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 62, 442-450 (2008).
32. Pea F, Pavan F, Lugatti E et al. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis. Clin. Pharmacokinet. 45, 287-295 (2006).
33. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr. Opin. Pulm. Med. 14, 595-599 (2008).
34. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178, 1139-1147 (2008).
35. Sullivan JT, Lettieri JT, Liu P, Heller AH. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin. Pharmacokinet. 40(Suppl. 1), 11-8 (2001).
36. Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int. J. Antimicrob. Agents 23, 421-429 (2004).
37. Anzueto A, Gotfried M, Wikler MA, Russo R, Nicholson SC. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. Clin. Ther. 24, 916-917 (2002).
38. Dimopoulos, G, Siempos II, Korbila IP, Manta KG, Falagas ME. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 132, 447-455 (2007). •• Excellent meta-analysis on the effectiveness of various classes of antibiotics on AECB.
39. Siempos II, Dimopoulos G, Korbila IP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 29, 1127-1137 (2007).
40. Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB. Levofloxacin 750 mg QD for five days versus amoxicillin/ clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients. Clin. Ther. 28, 1175-1180 (2006).
41. Petitpretz P, Chone C, Tremolieres F. Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval. Int. J. Antimicrob. Agents 30, 52-59 (2007).
42. Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med. 97, 242-249 (2003).
43. Wilson R, Allegra L, Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125, 953-964 (2004).
44. Wilson R, Jones P, Schaberg T, Arvis P, Duprat-Lomon I, Sagnier PP. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 61, 337-342 (2006).
45. Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents 29, 56-61 (2007).
46. Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J. Chemother. 14, 597-608 (2002).
47. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents 23, 129-137 (2004).
48. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res. 29, 314-328 (2001).
49. Urueta-Robledo, J, Ariza H, Jardim JR et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort. Respir. Med. 100, 1504-1511 (2006).
50. Miravitlles M, Ros F, Cobos A, Kubin R, Tillotson G. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience. Int. J. Clin. Pract. 55, 437-441 (2001).
51. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir. Med. 99, 955-965 (2005).
52. Schaberg T, Moller M, File T, Stauch K, Landen H. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin. Drug Investig. 26, 733-744 (2006).
53. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin. Infect. Dis. 41, 118-121 (2005).
54. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6, 629-640 (2006).
55. Amsden GW, Baird IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 123, 772-777 (2003).